We Bring Innovation to Healthcare
Antiphospholipid Syndrome (APS), also known as Hughes syndrome is an autoimmune disease defined by the development of venous and/or arterial thrombosis, often multiple, and pregnancy morbidity.
Endotelix is fully focused on innovation within the field of antiphospholipid syndrome. As such, our pipeline is centred on two main clinical developmental projects.
These projects, which include diagnostics and treatments, will significantly improve the management of APS and therefore the lives of the patients who suffer from it.
Endotelix is a privately held Swiss biotech start-up company and a spin-off from the University of Geneva. Endotelix is dedicated to providing fast, sensitive and reliable solutions for Antiphospholipid Syndrome including diagnostic tests and treatment options.